The Scripps Research Institute today announced it has entered into a five-year collaboration with Bristol-Myers Squibb Company (NYSE:BMY) focused on applying novel chemistry to drug discovery and synthesis.
"This agreement is an exciting development for The Scripps Research Institute," said Scripps Research President and CEO Michael A. Marletta. "It serves as a great example of how we will engage corporate partners in both understanding and treating disease. I look with anticipation to the outcome of this multi-lab collaboration.”
Scott Forrest, vice president for business development at Scripps Research, added, “This arrangement is exemplary of our forward-looking corporate partnership strategy, as the first of what we hope will be many such agreements existing in parallel.”
The collaboration will revolve around support for projects of mutual interest to Bristol-Myers Squibb and a number of Scripps Research chemistry laboratories. Scripps Research investigators and senior scientists from Bristol-Myers Squibb collaborated to develop research plans incorporated into the new agreement.
In broad terms, the research will utilize Scripps Research investigators’ expertise in applying chemistry methodologies to prepare novel synthetic intermediates and analogs for biological evaluation against Bristol-Myers Squibb targets.
For more information about licensing opportunities with Scripps Research, see the Office of Technology Transfer website at http://www.scripps.edu/research/technology/index.html
Send comments to: press[at]scripps.edu